Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 69Neoplasms 21Breast Neoplasms 21Fallopian Tube Neoplasms 18Prostatic Neoplasms 15Neoplasm Metastasis 9Pancreatic Neoplasms 8Endometrial Neoplasms 8Carcinoma, Ovarian Epithelial 8Glioblastoma 7Triple Negative Breast Neoplasms 6Lung Neoplasms 5Small Cell Lung Carcinoma 4Glioma 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Mesothelioma 3Melanoma 3Head and Neck Neoplasms 3Cystadenocarcinoma, Serous 3Cholangiocarcinoma 3Carcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Stomach Neoplasms 2Solid Tumor 2Sarcoma 2Prostatic Neoplasms, Castration-Resistant 2Ovarian Diseases 2

Interventions

niraparib 1luprolide acetate gel depot 1apalutamide 1Prednisone 1Androgen Antagonists 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-sensitive Prostate Cancer × niraparib × Clear all
NCT04497844 2026-05-11

AMPLITUDE

Janssen Research & Development, LLC

Phase 3 Active not recruiting
696 enrolled 15 charts 1 FDA
Genitourinary

Metastatic Castration-sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡